Community Mental Health Journal

, Volume 55, Issue 4, pp 702–708 | Cite as

Abuse and Effects of Salvia divinorum in a Sample of Patients Hospitalized for Substance Dependence

  • Antoine Karam
  • Aida Said
  • Chafika Assaad
  • Souheil Hallit
  • Georges Haddad
  • Dory Hachem
  • Francois KazourEmail author
Brief Report


The study goal is to document the prevalence of salvia use among patients admitted for detoxification of other illicit drug use and to determine its effect. This cross-sectional study included 47 heavy drug users who were admitted for detoxification of other illicit drug abuse at a psychiatric hospital in Lebanon. The prevalence of salvia use was 66%. The salvia effect started and dissipated rapidly (15 min). No significant difference was found between salvia and non-salvia users in terms of affect, cognition and somaesthesia subscales of the Hallucinogen Rating Scale. Ratings of intensity and volition subscales were higher in non-salvia users than salvia users, while perception score was higher in users. Salvia use was correlated with perceptual alteration and hallucinogenic effects.


Salvia Drug Substance Addiction Hallucinogen 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Addy, P. H. (2012). Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berlin), 220(1), 195–204.CrossRefGoogle Scholar
  2. Addy, P. H., Garcia-Romeu, A., Metzger, M., & Wade, J. (2015). The subjective experience of acute, experimentally-induced Salvia divinorum inebriation. Journal of Psychopharmacology, 29(4), 426–435.CrossRefGoogle Scholar
  3. Albertson, D. N., & Grubbs, L. E. (2009). Subjective effects of Salvia divinorum: LSD- or marijuana-like? Journal of Psychoactive Drugs, 41(3), 213–217.CrossRefGoogle Scholar
  4. Ansonoff, M. A., Zhang, J., Czyzyk, T., Rothman, R. B., Stewart, J., Xu, H., et al. (2006). Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. Journal of Pharmacology and Experimental Therapeutics, 318(2), 641–648.CrossRefGoogle Scholar
  5. Appel, J., & Kim-Appel, D. (2007). The rise of a new psychoactive agent: Salvia divinorum. International Journal of Mental Health and Addiction, 5(3), 248–253.CrossRefGoogle Scholar
  6. Baggott, M. J., Erowid, E., Erowid, F., Galloway, G. P., & Mendelson, J. (2010). Use patterns and self-reported effects of Salvia divinorum: An internet-based survey. Drug and Alcohol Dependence, 111(3), 250–256.CrossRefGoogle Scholar
  7. Chavkin, C., Sud, S., Jin, W., Stewart, J., Zjawiony, J. K., Siebert, D. J., et al. (2004). Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics, 308(3), 1197–1203.CrossRefGoogle Scholar
  8. Cunningham, C. W., Rothman, R. B., & Prisinzano, T. E. (2011). Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacological Reviews, 63(2), 316–347.CrossRefGoogle Scholar
  9. El-Khoury, J., & Sahakian, N. (2015). The association of Salvia divinorum and psychotic disorders: A review of the literature and case series. Journal Psychoactive Drugs, 47(4), 286–292.CrossRefGoogle Scholar
  10. Featherstone, R. E., Liang, Y., Saunders, J. A., Tatard-Leitman, V. M., Ehrlichman, R. S., & Siegel, S. J. (2012). Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiology of Disease, 47(3), 338–346.CrossRefGoogle Scholar
  11. González, D., Riba, J., Bouso, J. C., Gómez-Jarabo, G., & Barbanoj, M. J. (2006). Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug and Alcohol Dependence, 85(2), 157–162.CrossRefGoogle Scholar
  12. Hooker, J. M., Xu, Y., Schiffer, W., Shea, C., Carter, P., & Fowler, J. S. (2008). Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage, 41(3), 1044–1050.CrossRefGoogle Scholar
  13. Johnson, M. W., MacLean, K. A., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2011). Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence, 115(1–2), 150–155.CrossRefGoogle Scholar
  14. Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.CrossRefGoogle Scholar
  15. Kazour, F., Soufia, M., Rohayem, J., & Richa, S. (2016). Suicide risk of heroin dependent subjects in Lebanon. Community Mental Health Journal, 52(5), 589–596.CrossRefGoogle Scholar
  16. Kelly, B. C. (2011). Legally tripping: A qualitative profile of Salvia divinorum use among young adults. Journal of Psychoactive Drugs, 43(1), 46–54.CrossRefGoogle Scholar
  17. Khey, D. N., Miller, B. L., & Griffin, O. H. (2008). Salvia divinorum use among a college student sample. Journal of Drug Education, 38(3), 297–306.CrossRefGoogle Scholar
  18. Lange, J. E., Reed, M. B., Croff, J. M., & Clapp, J. D. (2008). College student use of Salvia divinorum. Drug and Alcohol Dependence, 94(1–3), 263–266.CrossRefGoogle Scholar
  19. MacLean, K. A., Johnson, M. W., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2013). Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berline), 226(2), 381–392.CrossRefGoogle Scholar
  20. McLellan, A. T., Luborsky, L., Woody, G. E., & O’Brien, C. P. (1980). An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. The Journal of Nervous and Mental Disease, 168(1), 26–33.CrossRefGoogle Scholar
  21. Miller, B. L., Griffin, O. H., Gibson, C. L., & Khey, D. N. (2009). Trippin’on Sally D: Exploring predictors of Salvia divinorum experimentation. Journal of Criminal Justice, 37(4), 396–403.CrossRefGoogle Scholar
  22. Nyi, P. P., Lai, E. P., Lee, D. Y., Biglete, S. A., Torrecer, G. I., & Anderson, I. B. (2010). Influence of age on Salvia divinorum use: Results of an Internet survey. Journal of Psychoactive Drugs, 42(3), 385–392.CrossRefGoogle Scholar
  23. Perron, B. E., Ahmedani, B. K., Vaughn, M. G., Glass, J. E., Abdon, A., & Wu, L. T. (2012). Use of Salvia divinorum in a nationally representative sample. The American Journal of Drug and Alcohol Abuse, 38(1), 108–113.CrossRefGoogle Scholar
  24. Prisinzano, T. E. (2005). Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sciences, 78(5), 527–531.CrossRefGoogle Scholar
  25. Ranganathan, M., Schnakenberg, A., Skosnik, P. D., Cohen, B. M., Pittman, B., Sewell, R. A., et al. (2012). Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biological Psychiatry, 72(10), 871–879.CrossRefGoogle Scholar
  26. Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., et al. (2002). Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist. Proceedings of the National Academy of Sciences, 99(18), 11934–11939.CrossRefGoogle Scholar
  27. Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry, 59(Suppl 20), 22–33 (quiz 4–57).Google Scholar
  28. Siebert, D. J. (1994). Salvia divinorum and salvinorin A: New pharmacologic findings. Journal of Ethnopharmacology, 43(1), 53–56.CrossRefGoogle Scholar
  29. Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R. (1994). Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry, 51(2), 98–108.CrossRefGoogle Scholar
  30. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (SAMHSA). (2008). The NSDUH report: Use of specific hallucinogens: 2006. Retreived from
  31. Sumnall, H. R., Measham, F., Brandt, S. D., & Cole, J. C. (2011). Salvia divinorum use and phenomenology: Results from an online survey. Journal of Psychopharmacology, 25(11), 1496–1507.CrossRefGoogle Scholar
  32. Valdes, L. J. 3rd (1994). Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A. Journal of Psychoactive Drugs, 26(3), 277–283.CrossRefGoogle Scholar
  33. Wu, L. T., Woody, G. E., Yang, C., Li, J. H., & Blazer, D. G. (2011). Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Substance Abuse and Rehabilitation, 2011(2), 53–68.CrossRefGoogle Scholar
  34. Zawilska, J. B., & Wojcieszak, J. (2013). Salvia divinorum: From Mazatec medicinal and hallucinogenic plant to emerging recreational drug. Human Psychopharmacology, 28(5), 403–412.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Antoine Karam
    • 1
    • 2
  • Aida Said
    • 3
  • Chafika Assaad
    • 3
  • Souheil Hallit
    • 1
    • 2
    • 4
    • 5
    • 6
    • 7
  • Georges Haddad
    • 1
    • 2
  • Dory Hachem
    • 1
  • Francois Kazour
    • 1
    • 7
    • 8
    • 9
    Email author
  1. 1.Psychiatric Hospital of the CrossJal EddibLebanon
  2. 2.Faculty of Medicine and Medical SciencesHoly Spirit UniversityJouniehLebanon
  3. 3.Faculty of SciencesLebanese UniversityBeirutLebanon
  4. 4.Faculty of PharmacyLebanese UniversityBeirutLebanon
  5. 5.Faculty of PharmacySaint Joseph UniversityBeirutLebanon
  6. 6.Occupational Health Environment Research TeamU1219 BPH Bordeaux Population Health Research Center Inserm - University of BordeauxBordeauxFrance
  7. 7.INSPECT-LB: Institut National de Sante Publique, Epidemiologie Clinique et Toxicologie, Faculty of Public Health,Lebanese UniversityBeirutLebanon
  8. 8.Faculty of MedicineSaint Joseph UniversityBeirutLebanon
  9. 9.INSERM U930, équipe 4 “Troubles affectifs”Université François-Rabelais de ToursToursFrance

Personalised recommendations